<DOC>
	<DOCNO>NCT00893555</DOCNO>
	<brief_summary>The objective study proposal determine whether pharmacologic optimization voriconazole mean therapeutic drug monitoring ( TDM ) result improved patient outcome ( efficacy safety ) cost-effective compare current standard care .</brief_summary>
	<brief_title>Pharmacologic Optimization Voriconazole</brief_title>
	<detailed_description>Patients haematological malignancy chemotherapy-induced prolonged neutropenia risk severe bacterial fungal infection . These opportunistic infection result prolonged hospital stay , increase cost great mortality . Voriconazole recommend first line agent invasive pulmonary aspergillosis . Retrospective observational study voriconazole serum concentration suggest serum concentration correlate toxicity clinical response . These observation however make small series patient data collect retrospectively . These inherent methodological flaw make impossible draw definite conclusion effect voriconazole serum level monitoring outcome IA , therefore consider insufficient proof recommend voriconazole concentration determination blood standard care . The impact call serum concentration guide dosing voriconazole treatment success evaluate prospective randomize clinical trial . For purpose , design prospective stratify cluster randomize cross-over trial therapeutic drug monitoring patient haematological disease develop IA . The order period ( TDM standard care , 12 month ) randomize per centre . During TDM episode , voriconazole dosage adjust achieve trough blood concentration predefined window 2-5 mg/L . A sample size n=192 need detect 20 % absolute reduction number treatment failure ( 40 % 20 % ) compare control .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>least 18 year age receive chemotherapy haematological malignancy receive hematopoietic stem cell transplant proven , probable possible invasive fungal disease accord EORTC/MSG criterion treatment voriconazole allergic voriconazole excipients age 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Invasive fungal infection</keyword>
	<keyword>hematological malignancy</keyword>
	<keyword>voriconazole</keyword>
	<keyword>therapeutic drug monitoring</keyword>
</DOC>